[go: up one dir, main page]

EA200801634A1 - Твердая фармацевтическая композиция, содержащая ирбесартан - Google Patents

Твердая фармацевтическая композиция, содержащая ирбесартан

Info

Publication number
EA200801634A1
EA200801634A1 EA200801634A EA200801634A EA200801634A1 EA 200801634 A1 EA200801634 A1 EA 200801634A1 EA 200801634 A EA200801634 A EA 200801634A EA 200801634 A EA200801634 A EA 200801634A EA 200801634 A1 EA200801634 A1 EA 200801634A1
Authority
EA
Eurasian Patent Office
Prior art keywords
solid pharmaceutical
pharmaceutical composition
composition containing
irbesartan
containing irbesartan
Prior art date
Application number
EA200801634A
Other languages
English (en)
Other versions
EA016579B1 (ru
Inventor
Миха Врбинц
Рената Яксе
Франци Бевец
Силво Зупанциц
Original Assignee
Крка, Д.Д. Ново Место
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Крка, Д.Д. Ново Место filed Critical Крка, Д.Д. Ново Место
Publication of EA200801634A1 publication Critical patent/EA200801634A1/ru
Publication of EA016579B1 publication Critical patent/EA016579B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится предпочтительно к твердым фармацевтическим препаратам, не содержащим поверхностно-активного вещества, содержащим в качестве активного ингредиента по меньшей мере одно из следующего: ирбесартан и его фармацевтически приемлемые соли и по меньшей мере один разрыхлитель. Предпочтительно активный ингредиент содержит ирбесартана гидрохлорид. Кроме того, настоящее изобретение относится к способу изготовления таких препаратов, включающему способ влажной грануляции (А) и способ прямой грануляции (Б).
EA200801634A 2006-01-09 2007-01-05 Твердый фармацевтический препарат, содержащий гидрохлорид ирбесартана, и способ его изготовления EA016579B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06000329A EP1806130B1 (en) 2006-01-09 2006-01-09 Solid pharmaceutical composition comprising irbesartan
PCT/EP2007/000074 WO2007080074A1 (en) 2006-01-09 2007-01-05 Solid pharmaceutical composition comprising irbesartan

Publications (2)

Publication Number Publication Date
EA200801634A1 true EA200801634A1 (ru) 2008-10-30
EA016579B1 EA016579B1 (ru) 2012-06-29

Family

ID=35744710

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801634A EA016579B1 (ru) 2006-01-09 2007-01-05 Твердый фармацевтический препарат, содержащий гидрохлорид ирбесартана, и способ его изготовления

Country Status (15)

Country Link
US (1) US20110045097A1 (ru)
EP (2) EP1806130B1 (ru)
CN (1) CN101370484B (ru)
AT (1) ATE462414T1 (ru)
CA (1) CA2636663A1 (ru)
DE (1) DE602006013261D1 (ru)
EA (1) EA016579B1 (ru)
ES (1) ES2340701T3 (ru)
HR (1) HRP20100216T1 (ru)
NO (1) NO20083183L (ru)
PL (1) PL1806130T3 (ru)
PT (1) PT1806130E (ru)
SI (1) SI1806130T1 (ru)
UA (1) UA95274C2 (ru)
WO (1) WO2007080074A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006006588A1 (de) * 2006-02-13 2007-08-16 Ratiopharm Gmbh Schnell freisetzende Irbesartan-haltige pharmazeutische Zusammensetzung
CA2682929A1 (en) * 2007-04-17 2008-10-23 Ratiopharm Gmbh Pharmaceutical compositions comprising irbesartan
PL2065035T3 (pl) 2007-11-28 2011-02-28 Lesvi Laboratorios Sl Preparaty farmaceutyczne zawierające irbesartan
WO2011141783A2 (en) 2010-04-13 2011-11-17 Micro Labs Limited Pharmaceutical composition comprising irbesartan
CN101912390A (zh) * 2010-08-08 2010-12-15 浙江华海药业股份有限公司 含厄贝沙坦的药用组合物
CN103191076B (zh) * 2013-04-27 2016-08-17 吕丕平 一种厄贝沙坦片剂的制备方法
JP6445923B2 (ja) * 2015-04-22 2018-12-26 ダイト株式会社 イルベサルタン含有錠剤の調製方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
TW201738B (ru) 1990-03-20 1993-03-11 Sanofi Co
US5541209A (en) * 1994-08-22 1996-07-30 Bristol-Myers Squibb Company Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative
FR2725987B1 (fr) 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
FR2780403B3 (fr) 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
TWI324074B (en) * 2001-10-09 2010-05-01 Bristol Myers Squibb Co Flashmelt oral dosage formulation
WO2003050110A1 (en) 2001-12-10 2003-06-19 Dr. Reddy's Laboratories Ltd. Amorphous form of 2-n-butyl-3-( (2-(1h-tetrazol-5-yl) (1,1'-biphenyl)-4-yl) methyl) -1,3-diazaspiro (4,4') non-1-en-4-one
PT1546135E (pt) 2002-07-16 2006-12-29 Teva Pharma Nova síntese de irbesartan
TR200301553A1 (tr) * 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
ATE493973T1 (de) * 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006013545A1 (en) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Pharmaceutical compositions of irbesartan
SI21849A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava hidrokloridnih soli tetrazolskega derivata
GB2419592A (en) * 2004-10-26 2006-05-03 Cipla Ltd Process for the preparation of irbesartan hydrochloride
WO2006076097A2 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
WO2006067601A1 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of irbesartan and hydrochlorothiazide and processes for their preparation

Also Published As

Publication number Publication date
WO2007080074A1 (en) 2007-07-19
PL1806130T3 (pl) 2010-08-31
HRP20100216T1 (hr) 2010-05-31
CN101370484B (zh) 2011-06-01
US20110045097A1 (en) 2011-02-24
EA016579B1 (ru) 2012-06-29
EP1806130B1 (en) 2010-03-31
DE602006013261D1 (de) 2010-05-12
CN101370484A (zh) 2009-02-18
SI1806130T1 (sl) 2010-06-30
ATE462414T1 (de) 2010-04-15
CA2636663A1 (en) 2007-07-19
UA95274C2 (ru) 2011-07-25
EP1981485B1 (en) 2014-10-08
PT1806130E (pt) 2010-05-11
EP1981485A1 (en) 2008-10-22
ES2340701T3 (es) 2010-06-08
NO20083183L (no) 2008-09-26
EP1806130A1 (en) 2007-07-11

Similar Documents

Publication Publication Date Title
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
NO20043367L (no) Oralt farmasoytisk preparat
UA95199C2 (en) Aqueous formulation of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP2178869A4 (en) INDOL COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS
DK2451445T3 (da) Fremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens
MX2007012443A (es) Formulaciones farmaceuticas orales que comprenden acido fenofibrico y/o sus sales.
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
ECSP088560A (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
DK1820506T3 (da) Dipyridamol-formuleringer med forlænget frigivelse og fremgangsmåde til fremstilling heraf
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
PL2094308T3 (pl) Trwały preparat pozajelitowy zawierający inhibitor RSV o strukturze benzodiazepiny
DE602005027540D1 (de) Feste formulierungen von ospemifen
MA32964B1 (fr) Formulation a effet retard d'octreotide avec niveau d'exposition constamment eleves
CY1112702T1 (el) Βελτιωμενη φαρμακευτικη συνθεση που περιεχει εναν αντισπασμωδικο παραγοντα πυρρολιδονης και μεθοδος για την παρασκευη της
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
TW200744583A (en) Statin stabilizing dosage formulations
ATE537822T1 (de) Antidepressivum
CY1114306T1 (el) Νεα συνθεση για τη θεραπευτικη αντιμετωπιση της ιδιοπαθους θρομβοκυτταραιμιας
WO2008004100A3 (en) Therapeutic compounds
TW200640933A (en) Anthelmintic compounds

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KZ RU